Multiparameter ranking of carbazoles for anti-trypanosome lead discovery

The criteria for the progression of hits in the discovery of leads for human African trypanosomiasis (HAT), a neglected disease caused by the microbial eukaryote <i>Trypanosoma brucei</i>, are not standardized. Hits are advanced upon meeting thresholds for drug-like molecules. Following those principles, pharmacokinetics (C<sub>max</sub> and AUC<sub>0-6h</sub>) and anti-trypanosome characteristics predicted the arrest of <i>T. brucei</i> proliferation in mice by three curaxins. Unexpectedly, while CBL0137 cured HAT in a mouse model, CBL0174 and CBL0187-structural analogs of CBL0137 with similar drug-like properties-failed to control <i>T. brucei</i> division. We here propose an alternative strategy that integrates physicochemical, metabolic, pharmacokinetic, pharmacodynamic, tissue distribution, and trypanocidality parameters into calculating a score for ranking compounds in hit-to-lead campaigns. Data from our studies of curaxins support the feasibility of this goal. Serum dropped the anti-trypanosome potency of CBL0174 and CBL0187 considerably. Delayed trypanocidal concentrations (DTC<sub>25</sub> and DTC<sub>90</sub>) were used to study modes of curaxin actions in trypanosomes. Efficacy of CBL0137 in mice correlated with (i) a high AUC<sub>0-6h</sub>: DTC<sub>90</sub> ratio, (ii) blocking of transferrin endocytosis, and (iii) the inhibition of protein synthesis. Hydroxylation of the carbazole prevented CBL0137 from inhibiting endocytosis of transferrin. The multiparametric score "Curaxin HAT lead efficacy (CHLE)" score was calculated using pharmacokinetic, physicochemical, metabolic, brain exposure, and pharmacodynamic data; CBL0137 was the highest scoring hit. Complementing these observations and predictive of performance of curaxins in mice, CBL0137, but not CBL0174 or CBL0187, was trypanocidal after the exposure of trypanosomes to AUC<sub>0-6h</sub> amounts of the hits for 6 hours <i>in vitro</i>. We discuss a role for CHLE scores in ranking curaxins for anti-HAT lead discovery. The principles used to develop CHLE scores may be used to calculate new ones for other scaffolds during the discovery of leads for HAT or other infectious diseases.

Authors

Institutions

Publication Details

Journal
Frontiers in Drug Discovery
Published
2024-08-15
DOI
https://doi.org/10.3389/fddsv.2024.1430927
Primary Topic
Trypanosoma species research and implications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multiparameter ranking of carbazoles for anti-trypanosome lead discovery

Kojo Mensa‐Wilmot, Carlos E. Sanz-Rodríguez, Michael P. Pollastri, Andrei A. Purmal et al.
Frontiers in Drug Discovery
Trypanosoma species research and implications
article

Multiparameter ranking of carbazoles for anti-trypanosome lead discovery

Kojo Mensa‐Wilmot, Carlos E. Sanz-Rodríguez, Michael P. Pollastri, Andrei A. Purmal, Amrita Sharma
article en

Abstract

The criteria for the progression of hits in the discovery of leads for human African trypanosomiasis (HAT), a neglected disease caused by the microbial eukaryote <i>Trypanosoma brucei</i>, are not standardized. Hits are advanced upon meeting thresholds for drug-like molecules. Following those principles, pharmacokinetics (C<sub>max</sub> and AUC<sub>0-6h</sub>) and anti-trypanosome characteristics predicted the arrest of <i>T. brucei</i> proliferation in mice by three curaxins. Unexpectedly, while CBL0137 cured HAT in a mouse model, CBL0174 and CBL0187-structural analogs of CBL0137 with similar drug-like properties-failed to control <i>T. brucei</i> division. We here propose an alternative strategy that integrates physicochemical, metabolic, pharmacokinetic, pharmacodynamic, tissue distribution, and trypanocidality parameters into calculating a score for ranking compounds in hit-to-lead campaigns. Data from our studies of curaxins support the feasibility of this goal. Serum dropped the anti-trypanosome potency of CBL0174 and CBL0187 considerably. Delayed trypanocidal concentrations (DTC<sub>25</sub> and DTC<sub>90</sub>) were used to study modes of curaxin actions in trypanosomes. Efficacy of CBL0137 in mice correlated with (i) a high AUC<sub>0-6h</sub>: DTC<sub>90</sub> ratio, (ii) blocking of transferrin endocytosis, and (iii) the inhibition of protein synthesis. Hydroxylation of the carbazole prevented CBL0137 from inhibiting endocytosis of transferrin. The multiparametric score "Curaxin HAT lead efficacy (CHLE)" score was calculated using pharmacokinetic, physicochemical, metabolic, brain exposure, and pharmacodynamic data; CBL0137 was the highest scoring hit. Complementing these observations and predictive of performance of curaxins in mice, CBL0137, but not CBL0174 or CBL0187, was trypanocidal after the exposure of trypanosomes to AUC<sub>0-6h</sub> amounts of the hits for 6 hours <i>in vitro</i>. We discuss a role for CHLE scores in ranking curaxins for anti-HAT lead discovery. The principles used to develop CHLE scores may be used to calculate new ones for other scaffolds during the discovery of leads for HAT or other infectious diseases.

Frontiers in Drug DiscoveryVol. 4
Northeastern University (US), University of Georgia (US), Kennesaw State University (US)
National Institutes of Health
Good health and well-being
Openalex Percentile: Top 79%
Trypanosoma species research and implications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.